| pubmed-article:6808540 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6808540 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:6808540 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:6808540 | lifeskim:mentions | umls-concept:C0034798 | lld:lifeskim |
| pubmed-article:6808540 | lifeskim:mentions | umls-concept:C0026388 | lld:lifeskim |
| pubmed-article:6808540 | lifeskim:mentions | umls-concept:C0205345 | lld:lifeskim |
| pubmed-article:6808540 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
| pubmed-article:6808540 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:6808540 | pubmed:dateCreated | 1982-9-24 | lld:pubmed |
| pubmed-article:6808540 | pubmed:abstractText | Chronic treatment of rats with the antipsychotic drug molindone (2.5 mg/kg) did not elicit behavioral supersensitivity to apomorphine (AP) (0.25 mg/kg) or increased striatal 3H-spiroperidol binding, whereas treatment with haloperidol (0.5-1.0 mg/kg) produced manifestations of dopaminergic supersensitivity in both paradigms. Chronic treatment with a high dose of molindone (20 mg/kg) elicited a small, but significant increase in behavioral sensitivity to AP (57%) which was, however, significantly less than that produced by 1 mg/kg haloperidol (126%, P less than 0.01). Apparent tolerance to elevation of striatal and frontal cortical 3,4-dihydroxyphenylacetic acid (DOPAC) levels was obtained with chronic molindone treatment (5 or 20 mg/kg). None of the molindone doses used (2.5-50 mg/kg) increased striatal dopamine receptor binding. Scatchard analyses revealed no change in either maximal binding capacity (Bmax) or dissociation constant (Kd). A significant (P less than 0.001) correlation of receptor binding activity and stereotypy score was obtained for haloperidol-, but not molindone-treated rats. These results with molindone in an animal model of tardive dyskinesia suggest that this drug may have a lower potential for eliciting this disorder in humans. | lld:pubmed |
| pubmed-article:6808540 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6808540 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6808540 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6808540 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6808540 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6808540 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6808540 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6808540 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6808540 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6808540 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6808540 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6808540 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6808540 | pubmed:issn | 0033-3158 | lld:pubmed |
| pubmed-article:6808540 | pubmed:author | pubmed-author:MellerEE | lld:pubmed |
| pubmed-article:6808540 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6808540 | pubmed:volume | 76 | lld:pubmed |
| pubmed-article:6808540 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6808540 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6808540 | pubmed:pagination | 222-7 | lld:pubmed |
| pubmed-article:6808540 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:6808540 | pubmed:meshHeading | pubmed-meshheading:6808540-... | lld:pubmed |
| pubmed-article:6808540 | pubmed:meshHeading | pubmed-meshheading:6808540-... | lld:pubmed |
| pubmed-article:6808540 | pubmed:meshHeading | pubmed-meshheading:6808540-... | lld:pubmed |
| pubmed-article:6808540 | pubmed:meshHeading | pubmed-meshheading:6808540-... | lld:pubmed |
| pubmed-article:6808540 | pubmed:meshHeading | pubmed-meshheading:6808540-... | lld:pubmed |
| pubmed-article:6808540 | pubmed:meshHeading | pubmed-meshheading:6808540-... | lld:pubmed |
| pubmed-article:6808540 | pubmed:meshHeading | pubmed-meshheading:6808540-... | lld:pubmed |
| pubmed-article:6808540 | pubmed:meshHeading | pubmed-meshheading:6808540-... | lld:pubmed |
| pubmed-article:6808540 | pubmed:meshHeading | pubmed-meshheading:6808540-... | lld:pubmed |
| pubmed-article:6808540 | pubmed:meshHeading | pubmed-meshheading:6808540-... | lld:pubmed |
| pubmed-article:6808540 | pubmed:meshHeading | pubmed-meshheading:6808540-... | lld:pubmed |
| pubmed-article:6808540 | pubmed:meshHeading | pubmed-meshheading:6808540-... | lld:pubmed |
| pubmed-article:6808540 | pubmed:meshHeading | pubmed-meshheading:6808540-... | lld:pubmed |
| pubmed-article:6808540 | pubmed:meshHeading | pubmed-meshheading:6808540-... | lld:pubmed |
| pubmed-article:6808540 | pubmed:meshHeading | pubmed-meshheading:6808540-... | lld:pubmed |
| pubmed-article:6808540 | pubmed:meshHeading | pubmed-meshheading:6808540-... | lld:pubmed |
| pubmed-article:6808540 | pubmed:year | 1982 | lld:pubmed |
| pubmed-article:6808540 | pubmed:articleTitle | Chronic molindone treatment: relative inability to elicit dopamine receptor supersensitivity in rats. | lld:pubmed |
| pubmed-article:6808540 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6808540 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:6808540 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
